Rare disease focus Target partners and customers in rare disease areas where there is high unmet medical need, leveraging Synageva’s track record of developing therapies for small patient populations to position as a specialist collaborator with specialized regulatory and access needs.

Strategic acquisition history Leverage the recent acquisition by Alexion for 8.4B to highlight value creation, stability, and capability to scale; use this to engage larger biopharma or specialty investors seeking proven exit routes or partnerships that complement Synageva’s pipeline.

Operational leadership Engage with senior operations expectations demonstrated by past COO appointment to emphasize disciplined program management, manufacturing readiness, and logistics expertise when proposing collaboration on late-stage development or commercialization plans.

Financial potential Position opportunities around mid-scale revenue generation (current revenue bracket) with substantial funding history ($597M) to support partnerships, co-development, or licensing deals that can accelerate rare-disease therapies to market while sharing risk.

Digital and global reach Utilize Synageva’s tech stack and web presence to propose digital collaboration platforms, patient engagement tools, and expanded market access strategies that leverage e-commerce, content delivery, and remote stakeholder engagement for rare disease treatments.